Approaches to increase specificity include exploiting differences in expression levels or interacting partners between tumor and normal tissues, designing inhibitors that disrupt tumor-specific protein–protein interactions or post-translationally modified forms of ALKBH5, and employing tumor-restricted delivery systems (for example, ligand-directed nanoparticles or antibody–drug conjugates). The gene discussed is ALKBH5; the disease is neoplasm.